Drug Profile
Rubitecan
Alternative Names: 9-NC; 9-Nitro-20(S)-camptothecin; 9-Nitro-camptothecin; Partaject Orathecin; Partaject rubitecan; RFS 2000Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator The Stehlin Foundation for Cancer Research
- Developer SuperGen
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Colorectal cancer; HIV infections; Leukaemia; Lung cancer; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 26 Apr 2006 Interim results from a US-based phase II clinical trial in patients with primary advanced Pancreatic cancer have been added to the Cancer therapeutic trials section
- 24 Jan 2006 SuperGen has withdrawn its MAA from the EMEA for rubitecan for the treatment of Pancreatic cancer
- 20 Jan 2006 Phase-III clinical trials in Pancreatic cancer in European Union (PO)